Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL210467 | 0.93 | KMT2A (0.64) | KMT2AMEN1HDAC6NPC1RAB9A | |
| SCHEMBL10251879 | 0.78 | HPGDS (0.51) | KMT2AMEN1HDAC6NPC1RAB9A | |
| SCHEMBL16756985 | 0.78 | RAB9A (0.55) | HDAC6NPC1RAB9APARP1ADORA3 | |
| SCHEMBL16757106 | 0.78 | ESR1 (0.52) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL20494920 | 0.76 | GRM5 (0.66) | KMT2AMEN1HDAC6NPC1RAB9A | |
| SCHEMBL17541933 | 0.76 | MEN1 (0.71) | KMT2AMEN1HDAC6NPC1RAB9A | |
| Ribose (Furanose) SCHEMBL6513521 | 0.76 | HK1 (0.47) | KMT2AMEN1HDAC6NPC1RAB9A | |
| SCHEMBL2772549 | 0.75 | NPC1 (0.52) | KMT2AHDAC6NPC1RAB9AMAPT | |
| SCHEMBL30369396 | 0.75 | NPC1 (0.60) | KMT2AMEN1HDAC6NPC1RAB9A | |
| SCHEMBL5694143 | 0.75 | MEN1 (0.51) | KMT2AMEN1HDAC6LMNACCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3765476-B1 | MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES | JANSSEN PHARMACEUTICA NV (BE) | 2025-11-26 | — | — | EP | disclosed |
| US-12428441-B2 | Modified nucleoside phosphoramidites | Janssen Biopharma, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250092400-A1 | Modified Oligonucleotides and Methods of Use | JANSSEN PHARMACEUTICA NV (BE) | 2025-03-20 | — | — | US | disclosed |
| US-20240309040-A1 | Modified Nucleoside Phosphoramidites | Janssen Biopharma, Inc. (US) | 2024-09-19 | — | — | US | disclosed |
| CN-109952378-B | Modified oligonucleotides and methods of use | 詹森生物制药有限公司 | 2024-09-17 | — | — | CN | disclosed |
| US-12077757-B2 | Modified oligonucleotides and methods of use | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-03 | — | — | US | disclosed |
| US-12030907-B2 | Modified nucleoside phosphoramidites | Janssen Biopharma, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240011029-A1 | MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-11 | — | — | US | disclosed |
| US-20230250125-A1 | NUCLEIC ACID POLYMERS | JANSSEN BIOPHARMA, LLC | 2023-08-10 | — | — | US | disclosed |
| US-11453881-B2 | Modified oligonucleotides for use in treatment of tauopathies | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030907-B2 | Modified nucleoside phosphoramidites | PNP, TYMP, NSUN2 | KMT2A 2651/4885MEN1 1069/4885HDAC6 3717/4885 |
| US-12077757-B2 | Modified oligonucleotides and methods of use | NSUN2, ADAR, POLM | KMT2A 1421/4885MEN1 3274/4885HDAC6 1820/4885 |
| US-11453881-B2 | Modified oligonucleotides for use in treatment of tauopathies | MAPT, PSEN2, NSUN2 | KMT2A 1363/4885MEN1 3848/4885HDAC6 311/4885 |
| US-12428441-B2 | Modified nucleoside phosphoramidites | MTAP, PNP, NT5C3B | KMT2A 3110/4885MEN1 2098/4885HDAC6 2722/4885 |
| US-20230250125-A1 | NUCLEIC ACID POLYMERS | NSUN2, NSUN3, RNGTT | KMT2A 1223/4885MEN1 3531/4885HDAC6 1015/4885 |
| US-20240011029-A1 | MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES | MAPT, PSEN2, NSUN2 | KMT2A 1363/4885MEN1 3848/4885HDAC6 311/4885 |
| US-20250092400-A1 | Modified Oligonucleotides and Methods of Use | NSUN2, ADAR, POLM | KMT2A 1499/4885MEN1 3470/4885HDAC6 1837/4885 |
| US-20240309040-A1 | Modified Nucleoside Phosphoramidites | MTAP, PNP, NT5C3B | KMT2A 3110/4885MEN1 2098/4885HDAC6 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.